OneCell Diagnostics, a cancer diagnostics startup, has successfully raised $16 million in its Series A funding round led by Celesta Capital. The funding round also saw participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures.
The fresh capital will be used to expand into the US market and scale the deployment of OncoIndx Alfa, OneCell’s next-generation liquid biopsy test designed to detect circulating tumor cells. The test is heralded as a significant advancement in precision oncology, offering a non-invasive and comprehensive approach to cancer diagnostics.
Cutting-edge technology for Precision Oncology
Founded in 2021, OneCell Diagnostics leverages advanced technologies such as next-generation sequencing (NGS), artificial intelligence (AI), machine learning (ML), and multi-omics data analytics to develop robust biomarkers. These tools enable a deeper understanding of cancer biology and provide insights into disease progression, recurrence, and treatment response.
“We envision a future where high-quality, life-saving cancer diagnostics are accessible to everyone. This funding is a validation of our mission,” said Mohan Uttarwar, CEO and co-founder of OneCell Diagnostics.
The OncoIndx Alfa Advantage
The OncoIndx Alfa liquid biopsy offers detailed biomarkers that support precision diagnosis and personalized treatment strategies. Its applications include monitoring treatment response, detecting disease progression, and identifying recurrence with enhanced accuracy.
To date, the company has tested its cell biopsy technology on nearly 10,000 patients in India, achieving remarkable success in clinical applications.
Strategic Partnerships and Vision
OneCell Diagnostics collaborates with leading institutions such as the All India Institute of Medical Science (AIIMS) in New Delhi and the Tata Memorial Centre. The company also boasts strategic academic and industry partnerships with globally renowned institutions like Harvard Medical School and Stanford University.
With this funding round, OneCell aims to bring its innovative diagnostic solutions to the US market, bridging gaps in cancer detection and enabling earlier, more precise interventions.
